Preparation method of (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1

Background and overview[1] Ezetimibe was jointly developed by Schering-Plough and Merck for the treatment of hyperlipidemia. It was approved by the U.S. FDA in 2002 under the trade name Zetia. Its chemical name is: 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl) -2-propionolactam. Hyperlipidemia is an important risk factor for the occurrence of cardiovascular diseases such as atherosclerosis. Lowering the total cholesterol…